1 Min Read
Oct 15 (Reuters) - Santhera Pharmaceuticals Holding AG:
* SANTHERA RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EU FOR POL6014 IN CYSTIC FIBROSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.